SCHEMBL19970751

SCHEMBL19970751

O=C(c1ccc2nc(-c3ccccc3)[nH]c2c1)N1CCN(Cc2cccc(OC(F)(F)F)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.55
ACHE P22303 2/20 0.55
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
RECQL P46063 1/20 0.53
KMT2A Q03164 1/20 0.53
CHEK2 O96017 6/20 0.53
HDAC6 Q9UBN7 1/20 0.52
STAT3 P40763 1/20 0.52
MGLL Q99685 4/20 0.51
RUNX1 Q01196 1/20 0.51
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SLC2A1 P11166 1/20 0.49
ACACB O00763 1/20 0.49
ACACA Q13085 1/20 0.49
MAPK14 Q16539 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970750 0.93 MEN1 (0.53) BCHEACHEKDM4EALDH1A1LMNA
SCHEMBL19970885 0.92 BCHE (0.56) BCHEACHECHEK2HDAC6MGLL
SCHEMBL19970865 0.91 STAT3 (0.51) BCHEACHEKDM4EALDH1A1LMNA
SCHEMBL19970749 0.89 RUNX1 (0.56) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL19970753 0.88 RUNX1 (0.59) BCHEACHECHEK2HDAC6RUNX1
SCHEMBL19970787 0.86 STAT3 (0.48) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL19970864 0.85 STAT3 (0.51) KDM4EALDH1A1LMNAMEN1MAPT
SCHEMBL19970884 0.85 LSS (0.54) BCHEACHEALDH1A1LMNACHEK2
SCHEMBL19970807 0.84 ACACB (0.62) BCHEACHECHEK2HDAC6MGLL
SCHEMBL19970859 0.83 NAMPT (0.52) BCHEACHEMEN1KMT2ACHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS BCHE 2347/4885ACHE 3553/4885KDM4E 1873/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS BCHE 2347/4885ACHE 3553/4885KDM4E 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.